series-c-plus
Stage
2015
Founded
1
Investors
About
Adagene is a Nasdaq-listed, clinical-stage biopharmaceutical company that discovers and designs therapeutic antibodies and antibody-based cancer immunotherapies using proprietary protein engineering and discovery platforms. The company develops wholly owned and partnered antibody programs, including clinical-stage candidates targeting oncology indications.
Explore Adagene's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.